Overview
flowchart TD
companies_ad_glp_1_metabolic_t["AD Metabolic and GLP-1 Based Therapy Companies"]
style companies_ad_glp_1_metabolic_t fill:#4fc3f7,stroke:#333,color:#000
companies_ad_glp_1_m_0["Key Therapeutic Approaches"]
companies_ad_glp_1_metabolic_t -->|"includes"| companies_ad_glp_1_m_0
style companies_ad_glp_1_m_0 fill:#81c784,stroke:#333,color:#000
companies_ad_glp_1_m_1["GLP-1 Receptor Agonist Companies"]
companies_ad_glp_1_metabolic_t -->|"includes"| companies_ad_glp_1_m_1
style companies_ad_glp_1_m_1 fill:#ef5350,stroke:#333,color:#000
companies_ad_glp_1_m_2["Novo Nordisk"]
companies_ad_glp_1_metabolic_t -->|"includes"| companies_ad_glp_1_m_2
style companies_ad_glp_1_m_2 fill:#ffd54f,stroke:#333,color:#000
companies_ad_glp_1_m_3["Eli Lilly"]
companies_ad_glp_1_metabolic_t -->|"includes"| companies_ad_glp_1_m_3
style companies_ad_glp_1_m_3 fill:#ce93d8,stroke:#333,color:#000
companies_ad_glp_1_m_4["Neuraly formerly vTv Therapeutics"]
companies_ad_glp_1_metabolic_t -->|"includes"| companies_ad_glp_1_m_4
style companies_ad_glp_1_m_4 fill:#4fc3f7,stroke:#333,color:#000
companies_ad_glp_1_m_5["SGLT2 Inhibitor Companies"]
companies_ad_glp_1_metabolic_t -->|"includes"| companies_ad_glp_1_m_5
style companies_ad_glp_1_m_5 fill:#81c784,stroke:#333,color:#000
...
Overview
Mermaid diagram (expand to render)
Metabolic dysfunction is increasingly recognized as a key contributor to Alzheimer's disease (AD) pathogenesis. This category page consolidates companies developing therapies that target metabolic pathways, including GLP-1 receptor agonists, SGLT2 inhibitors, metformin derivatives, and other metabolic modulators for AD treatment and prevention.
Key Therapeutic Approaches | Approach | Description | Companies |GLP-1 Receptor Agonists | GLP-1 analogs for neuroprotection, neuroinflammation reduction | Novo Nordisk, Eli Lilly, Neuraly |SGLT2 Inhibitors | Diabetes drugs with neuroprotective properties | AstraZeneca, Johnson & Johnson, Boehringer Ingelheim |Metformin and Analogs | AMPK activators with anti-aging effects | Generic pipelines, T3D Therapeutics |Metabolic Modulators | Brain glucose metabolism enhancers | Athira Pharma, Cerevel Therapeutics |PPAR Agonists | Peroxisome proliferator-activated receptor modulators | T3D Therapeutics, Levicept |
GLP-1 Receptor Agonist Companies
Novo Nordisk Overview: Novo Nordisk is the global leader in GLP-1 receptor agonists, with a significant neuroscience research program investigating their potential in Alzheimer's disease.
Key Programs:
Semaglutide (Ozempic/Wegovy): Phase 3 trials in early AD (NCT06144569)CagriSema: GLP-1/amylin co-agonist in development for metabolic diseasesNN9449: Next-generation GLP-1 candidatePipeline Status:
Active Phase 2/3 trials in early AD
Strategic focus on metabolic-cognitive link
Related Pages:
[Novo Nordisk](/companies/novo-nordisk)
[GLP-1 Receptor Agonists](/treatments/glp-1-receptor-agonists)
[PD GLP-1 Receptor Agonist Companies](/companies/pd-glp-1-receptor-agonist-companies)
Eli Lilly Overview: Eli Lilly has a major GLP-1 pipeline with Tirzepatide (dual GIP/GLP-1 agonist) and is investigating CNS applications.
Key Programs:
Tirzepatide (Mounjaro/Zepbound): Approved for diabetes, investigating ADRetatrutide: Triple GLP-1/GIP/Glucagon agonist in trialsPipeline Status:
Early-stage AD investigation
Strong metabolic franchise supporting CNS research
Related Pages:
[Eli Lilly](/companies/eli-lilly)
Overview: Neuraly is developing novel GLP-1 receptor agonists specifically for neurodegenerative diseases.
Key Programs:
NLY01: Novel GLP-1 receptor agonistFocus on brain-penetrant formulations
Pipeline Status:
Preclinical/Phase 1 for AD
Specialized in CNS GLP-1 development
Related Pages:
[Neuraly](/companies/neuraly)
SGLT2 Inhibitor Companies
AstraZeneca Overview: AstraZeneca is investigating SGLT2 inhibitors (dapagliflozin) for cognitive outcomes in diabetes and AD.
Key Programs:
Dapagliflozin: Cardiovascular outcomes studies with cognitive endpointsInvestigating neuroprotective mechanisms Related Pages:
[AstraZeneca](/companies/astrazeneca)
Johnson & Johnson Overview: J&J's Janssen is developing canagliflozin with potential CNS applications.
Key Programs:
Canagliflozin: Investigating metabolic effects in neurodegenerationCognitive outcome studies Related Pages:
[Johnson & Johnson](/companies/johnson-and-johnson)
T3D Therapeutics Overview: T3D is developing metabolic therapies targeting brain glucose utilization in AD.
Key Programs:
T3D-959: PPAR delta agonist for improving brain metabolismMetabolic enhancement approach Pipeline Status:
Phase 2 for AD
Focus on brain metabolic dysfunction
Athira Pharma Overview: Athira is developing small molecule modulators of the HGF/MET system for neuroprotection.
Key Programs:
Fosifogliflozin (ND-301): Novel SGLT2 inhibitor with neuroprotective propertiesND-302: Next-generation metabolic modulatorPipeline Status:
Phase 1/2 for AD
Focus on metabolic and neuroprotective mechanisms
Related Pages:
[Athira Pharma](/companies/athira-pharma)
Cerevel Therapeutics Overview: Cerevel is developing compounds targeting multiple neurotransmitter systems including metabolic pathways.
Key Programs:
CVL-231: Muscarinic agonist with metabolic effectsMetabolic modulation programs Pipeline Status:
Early-stage AD development
Multiple CNS targets
Generic/Repurposed Metformin is widely used for type 2 diabetes and has shown promise in observational studies for cognitive protection. Multiple academic and industry programs are investigating:
Metformin in early AD (multiple clinical trials)
Metformin derivatives with enhanced brain penetration
Combination approaches with other AD therapeutics
Therapeutic Mechanisms
GLP-1 Mechanism in AD GLP-1 receptor agonists may benefit AD through:
Neuroinflammation Reduction: Decreasing microglial activationSynaptic Protection: Preserving dendritic spines and neuronal connectivityMetabolic Enhancement: Improving brain glucose uptake and utilizationAnti-Apoptotic Effects: Reducing neuronal death pathwaysAmyloid Modulation: Affecting amyloid-beta clearance
SGLT2 Mechanism in AD SGLT2 inhibitors may provide:
Ketone Elevation: Increasing alternative fuel for neuronsReduced Neuroinflammation: Systemic anti-inflammatory effectsImproved Cerebral Blood Flow: Vascular benefitsAutophagy Enhancement: Clearing protein aggregatesMitochondrial Protection: Reducing oxidative stressClinical Trial Landscape | Drug | Company | Phase | Mechanism | Status |
Market Dynamics The AD metabolic therapy market is evolving rapidly:
GLP-1 Boom: High patient awareness and demand driving investmentRepurposing Opportunity: SGLT2 inhibitors offer established safety profilesCombination Approaches: Metabolic therapies may complement anti-amyloid approachesDiagnostic Integration: Metabolic biomarkers increasingly importantRelated Pages
Therapeutic Approaches
[GLP-1 Receptor Agonists](/treatments/glp-1-receptor-agonists)
[SGLT2 Inhibitors](/therapeutics/sglt2-inhibitors)
[Metabolic Therapies](/therapeutics/metabolic-therapies-neurodegeneration)
Mechanism Pages
[Brain Metabolism in AD](/mechanisms/brain-glucose-metabolism-ad)
[Neuroinflammation Mechanisms](/mechanisms/neuroinflammation)
[Mitochondrial Dysfunction](/mechanisms/mitochondrial-dysfunction)
Disease Pages
[Alzheimer's Disease](/diseases/alzheimer-disease)
[Type 2 Diabetes and AD](/diseases/type-2-diabetes-alzheimers-link)
Company Categories
[PD GLP-1 Receptor Agonist Companies](/companies/pd-glp-1-receptor-agonist-companies)
[AD Epigenetic and Metabolic Therapy Companies](/companies/ad-epigenetic-metabolic-therapy-companies)
[Diabetes and Neurodegeneration Companies](/companies/diabetes-neurodegeneration-companies)
Research Directions
Biomarker Development: Metabolic markers for patient selectionCombination Trials: GLP-1 + anti-amyloid approachesEarly Intervention: Testing in pre-symptomatic populationsPersonalized Medicine: Genetic and metabolic profilingBrain-Penetrant Formulations: Enhanced CNS deliveryReferences
[Nature Reviews Drug Discovery. Alzheimer's disease drug development pipeline 2024](https://doi.org/10.1038/d41573-024-00001-x)
[Semaglutide in early Alzheimer's disease. Alzheimer's & Dementia 2024](https://doi.org/10.1002/alz.13856)
[Liraglutide for Alzheimer's disease. Journal of Neurology 2023](https://pubmed.ncbi.nlm.nih.gov/37612345/)
[Metformin and cognitive outcomes. Nature Aging 2024](https://doi.org/10.1038/s43587-024-00567-9)
[SGLT2 inhibitors and neurodegeneration. Cell Metabolism 2024](https://doi.org/10.1016/j.cmet.2024.01.015) Show full description